Baxter International (BAX) Stock Summary Baxter International received a consensus "Reduce" rating from 14 brokerages with an average 12-month price target of $20.10. In recent earnings, the company reported Q4 earnings per share of $0.44, which missed analyst estimates. However, revenue of $2.97 billion exceeded expectations. The company declared a quarterly dividend of $0.01 per share, payable on April 1st. Goldman Sachs lowered its price target on BAX. UBS maintained a Neutral rating on the stock. The stock is holding near post-earnings recovery levels while the broader healthcare sector weakens.
Read full analysisBaxter International (BAX) Stock Summary Baxter International received a consensus "Reduce" rating from 14 brokerages with an average 12-month price target of $20.10. In recent earnings, the company reported Q4 earnings per share of $0.44, which missed analyst estimates. However, revenue of $2.97 billion exceeded expectations. The company declared a quarterly dividend of $0.01 per share, payable on April 1st. Goldman Sachs lowered its price target on BAX. UBS maintained a Neutral rating on the stock. The stock is holding near post-earnings recovery levels while the broader healthcare sector weakens.
Baxter International is a major medical devices and healthcare products company focused on renal care, hospital products, and surgical instruments. The company is navigating a turnaround after spinning off its kidney care business, but persistent margin pressure and elevated debt have complicated the recovery. A Q4 earnings miss and weak 2026 guidance triggered a 16% selloff on Feb 12, and the stock is now consolidating amid a consensus analyst "Reduce" rating.